Martijn Arns

Biomarker-driven stratified psychiatry: from stepped-care to matched-care in mental health nature.com/articles/s4422… First stratification biomarker that helps stratify between antidepressant treatments, taking level of treatment (eg. first-line vs. second-line treatment) into…

One of @atai_life's remaining non–wholly owned programs, inadascamine (RL-007), has shown modest but consistent numerical improvements across the overall MCCB neurocognitive composite in patients with cognitive impairment associated with schizophrenia (CIAS), but didn’t make its…

Congrats Neil et al, and another great example of blinded out-of-sample replication using TDBRAIN+ For those interested, access to the large open access TDBRAIN database can be found here: brainclinics.com/resources/tdbr…

nature.com/articles/s4422…

med.stanford.edu/news/all-news/…

New infographic on the ability of #TMS to modulate the autonomic nervous system as a mechanism to treat #depression. thanks to Michael Smith Health Research Foundation for their support. researchgate.net/publication/39…

x.com/i/article/1946…

Food for thought on the use of the "active" sham in several systems - creative take on the current situation from a great group of thinkers. Trigeminal Nerve Stimulation as a Semi-Active Control Condition in TMS... sciencedirect.com/science/articl…

Glad to see this published: Trigeminal nerve stimulation as a 'semi-active' TMS control condition: Heart-Brain Coupling identifying 'sham' response to TMS. Implications for power calculation, future meta-analyses and TMS trial design. brainstimjrnl.com/article/S1935-… Great collaboration…

Proud to be part of the team!🙏🧠⚡️📚 pubmed.ncbi.nlm.nih.gov/40464151/

@hubermanlab what is the best EEG-based model of plasticity that you’re aware of?

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH Research's Dosing Model Our notes from this morning's conference call, where company leadership discussed the BPL-003 results and took aim at their closest competitor's model. Read more: psychedelicalpha.com/news/beckley-a…

Yesterday, we celebrated the culmination of a remarkable journey with the completion of the 10th @Brainclinics Foundation PhD. This milestone has yielded a wealth of new insights and discoveries that have positively impacted numerous patients worldwide. For access to all the…

Yesterday Dr. @AmouriePrentice succesfully defended her PhD, join me in congratulating her with a great achievement. Her PhD focused on EEG biomarkers associated with treatment resistance and several chapters that advanced our understanding of Orbitofrontal cortex TMS in…

Great news and yet another significant step forward for psychedelic medicine! Today, @atai_life and @BeckleyPsytech announced (very!) positive topline results from the long-awaited Phase 2b trial of a single dose of BPL‑003 (5-MeO-DMT) in 193 patients living with…

Very exciting data indeed! Maintained clinical benefit over 2 months for single BPL-003 (aka 5-MeO-DMT) treatment within a 2hr treatment window in large sample of almost 200 patients.

New speaker announcement: Joseph Taylor (Harvard University) will present at the Brainclinics TMS Masterclass and Certification Course his latest results and insights titled: From Scalp to Circuit: Evolving TMS Targeting Approaches.

📢 Speaker Highlight: @JonathanDownar Join us in Nijmegen, Netherlands (Sept 30-Oct 2) for his talk: 'From one-session-a-day to TMS-in-a-day: The ONE-D trial' at the Brainclinics TMS Masterclass 🔗 Register today: brainclinics.com/masterclass/ma…

📢 Speaker Highlight: @andreashorn_ Join us in Nijmegen, Netherlands (Sept 30-Oct 2) for his talk: 'Toward connectomic based neuromodulation' at the @Brainclinics TMS Masterclass 🔗 Register today: brainclinics.com/masterclass/ma…